Boston Scientific schedules October 28 results: 75 cents EPS for Boston Scientific stock

Published on 10/27/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted earnings per share rose 15.00 percent in Q2 2026. Boston Scientific stock costs EUR 40.33 on October 27, 2026 at 5:15 p.m. CEST.

October 28 earnings checkpoint

Boston Scientific expects third-quarter earnings per share of USD 0.75 on October 28, 2026.
The average analyst target is USD 57.82 from 30 analysts.
Boston Scientific stock costs EUR 40.33 at Lang & Schwarz on October 27, 2026 at 5:15 p.m. CEST.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific scheduled its third-quarter results for October 28, 2026, with analysts expecting earnings per share of USD 0.75, according to Investing.com. Boston Scientific was trading at EUR 40.33 at Lang & Schwarz on October 27, 2026 at 5:15 p.m. CEST.

Analyst targets remain divided

MarketScreener lists a USD 57.82 average target from 30 analysts for Boston Scientific. The same page records Bernstein cutting its target from USD 60.00 to USD 54.00 on October 2, 2026 while maintaining an Outperform rating, according to MarketScreener. The spread between the USD 54.00 individual target and the USD 57.82 average underlines the range of views ahead of the report.

Q2 growth faces a tougher test

Boston Scientific generated USD 5.442 billion in revenue during the second quarter of 2026, up 7.50 percent from the prior-year quarter. Adjusted earnings per share rose 15.00 percent to USD 0.86, according to Investing.com. The report also said an August cyberattack disrupted manufacturing and order processing, making the third-quarter figures a test of how quickly operations recovered.

Valuation and reporting date

The NYSE-listed company had a market capitalization of USD 64.0 billion and a trailing price-to-earnings ratio of 18.48 as of October 27, 2026. Its 52-week range was USD 41.39 to USD 105.65, leaving the upcoming report as the next major dated operating checkpoint.

For investors, the key comparison is between the USD 5.442 billion second-quarter revenue base and the USD 5.12 billion analyst revenue expectation cited for the third quarter. That would represent a sequential decline of 5.92 percent, while the expected USD 0.75 earnings per share would be 12.79 percent below the second-quarter USD 0.86 figure.

Boston Scientific stock before results

The October 28 release will put the cyber disruption, product demand and the company's full-year outlook into one set of numbers. The company develops medical devices used in interventional procedures across cardiovascular care, endoscopy, urology and neuromodulation.

The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.